Registrational study of pelareorep + paclitaxel in HR+/HER2- metastatic breast cancer
Latest Information Update: 10 Oct 2024
At a glance
- Drugs Paclitaxel (Primary) ; Pelareorep (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Registrational; Therapeutic Use
- 10 Oct 2024 New trial record
- 04 Oct 2024 According to an Oncolytics Biotech media release, the strong efficacy results from BRACELET-1 provide the foundation for a large Phase 2 study designed to support an accelerated approval. Company anticipated to Initiate registrational study of pelareorep + paclitaxel in HR+/HER2- metastatic breast cancer in H1 2025.
- 04 Oct 2024 According to Oncolytics Biotech media release, enrollment in the registration-enabling study is expected to commence in the first half of 2025.